Compare Sana Biotechnology Inc (SANA) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Sana Biotechnology Inc trades at $3.77 (market cap $1.13B), while Invesco S&P 500 High Div Low Volatility ETF trades at $52.45. The key difference: Invesco S&P 500 High Div Low Volatility ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | SPHD | |
|---|---|---|
Market Cap | $1.13B | — |
Sector | Health | — |
52-Week High | $5.92 | $53.55 |
52-Week Low | $2.68 | $46.96 |
Enterprise Value | $1.05B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
SPHD trades at $52.405, showing minimal daily movement with a slight decline of 0.01%. The ETF maintains a bullish technical signal from moving averages, while oscillators indicate neutrality. Recent news highlights its focus on high dividends and low volatility, appealing to income investors seeking stability amid market swings. Dividend payments are scheduled for 2026, reinforcing its income-generating strategy.
The outlook for SPHD is stable, supported by its dividend yield and low-volatility approach, attracting retirees and risk-averse investors. Key risks include interest rate sensitivity and broader market downturns, which could impact dividend sustainability and NAV. Analyst sentiment remains positive due to consistent income appeal in volatile environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
